Dr. David J. Warrow, M.D.
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- University of Michigan Medical School (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 1,990
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: University of Michigan Medical School
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
MD license D0075771 · PA license MD454038 · VA license 0101253627 · WV license 26567 -
Retina Specialist (Ophthalmology) Physician
MD license D0075771 · PA license MD454038 · VA license 0101253627 · WV license 26567
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Wellspan Chambersburg Hospital Chambersburg, PA
Medical groups
- Cumberland Valley Retina Consultants PC (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,990
- Services billed
- 6,703,721
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Chloroprocaine hcl ophthalmic, 3% gel, 1 mg | 1,386,400 | 578 |
| Injection, faricimab-svoa, 0.1 mg | 69,840 | 113 |
| Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 29,145 | 511 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 15,240 | 232 |
| Imaging of retina | 8,169 | 1,824 |
| Injection of drug into eye | 7,264 | 731 |
| Established patient office or other outpatient visit, 30-39 minutes | 4,283 | 1,665 |
| Extended exam of the back part of the eye with retinal drawing | 4,139 | 1,738 |
| Photography of the retina | 2,342 | 902 |
| Exam of the internal drainage system of eye | 2,043 | 1,263 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ofloxacin Other prescribers in Hagerstown, MD | 361 |
| Prednisolone Acetate Other prescribers in Hagerstown, MD | 323 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Hagerstown, MD | 158 |
| Brimonidine Tartrate Other prescribers in Hagerstown, MD | 101 |
| Latanoprost Other prescribers in Hagerstown, MD | 84 |
| Ketorolac Tromethamine Other prescribers in Hagerstown, MD | 84 |
| Atropine Sulfate | 34 |
| Timolol Maleate Other prescribers in Hagerstown, MD | 32 |
| Acetazolamide Er (acetazolamide) Other prescribers in Hagerstown, MD | 27 |
| Simbrinza (brinzolamide/brimonidine tart) Other prescribers in Hagerstown, MD | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 52 payments worth $2,110 in total to this clinician.
| Harrow Eye, LLC | $452 |
|---|---|
| Apellis Pharmaceuticals, Inc. | $417 |
| Mallinckrodt Hospital Products Inc. | $287 |
| Genentech USA, Inc. | $168 |
| Neurotech Pharmaceuticals, Inc. | $164 |
| Astellas Pharma Global Development | $127 |
| Ani Pharmaceuticals, Inc. | $120 |
| Sun Pharmaceutical Industries Inc. | $115 |
| Food and Beverage | $2,110 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $577,709 in research payments for these studies, mostly to the institutions running them.
- JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1…
Hoffmann-la Roche Limited - A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704 - JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862
Boehringer Ingelheim International GmbH - A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema
Boehringer Ingelheim International GmbH - Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
Ani Pharmaceuticals, Inc. · Status unknown · NCT05322070
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.